Menu
Lausanne, Switzerland, and Boston, United States – February 20, 2020: SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that former Foundation Medicine CEO Troy Cox has been elected as Chairman of the Board of Directors, effective March 1, 2020. He is replacing Antoine Duchateau, who has served as chairman since 2013 and will continue as a board member. Cox joined the company in July of 2019 as a member of the board.
“This announcement signals how much of an asset Troy has been for SOPHiA GENETICS in this short amount of time,” said Jurgi Camblong, CEO and Co-founder. “I am delighted that he will assume the chairmanship of the company’s board, as his impressive expertise will help us to further expand our community of partners and the scope of new clinical-grade applications to further the success of our mission. I am deeply grateful to Antoine Duchateau for his outstanding guidance over the past 6 years as Chairman of the Board of Directors. His experience has been extremely valuable in driving SOPHiA GENETICS to its current position.”
Recent technological advances help SOPHiA GENETICS leverage even more multi-modal data, ultimately leading SOPHiA into a new era in healthcare. Fast and accurate diagnostics, personalized treatment options, longitudinal patient monitoring and drug development optimization are the concrete benefits of Data-Driven Medicine. This idea has shaped Troy Cox’s entire career, and his election as Chairman of the Board is a direct testimony thereof.
A healthcare industry visionary leader, Troy Cox formerly served as CEO of Foundation Medicine (FMI), where his work was recognized by the acquisition of the company by Roche in 2018. Prior to FMI, he led US BioOncology for a period of unprecedented growth as Senior Vice President and Officer at Genentech, participating in the launch of nearly half of the products. Earlier on, Mr. Cox held executive and senior positions at numerous healthcare companies including UCB BioPharmaceuticals, Sanofi-Aventis, and Schering-Plough.
“I’m proud to take a leadership role at this important time of expansion and to be part of SOPHiA GENETICS mission. Thanks to its global and universal approach that already benefits more than 1,000 hospital partners, SOPHiA is uniquely positioned to lead and promote an important movement in the entire ecosystem” said Troy Cox. “Together, we democratize Data-Driven Medicine, enabling clinical experts to access the full potential of new-generation health data and positively impact patients’ lives all around the world.”
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
